...
首页> 外文期刊>Vaccine >Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine
【24h】

Oculo-respiratory syndrome following influenza vaccination: evidence for occurrence with more than one influenza vaccine

机译:接种流感疫苗后的眼呼吸综合征:有一种以上流感疫苗发生的证据

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We assessed the occurrence of oculo-respiratory syndrome (ORS) following two influenza vaccines: Fluviral(R) (Shire Biologics) or Vaxigrip(R) (Aventis Pasteur). ORS was identified amongst 5.3 and 4.6% of recipients, respectively (P = 0.54). With both vaccines, the risk of ORS was much greater in individuals who had ORS the previous year (2000) than in those without such history. In multivariate analysis, the odds ratio for ORS for patients with a prior history of ORS varied between 9.4 and 9.6 (P < 0.001) whereas that comparing Fluviral(R) and Vaxigrip(R) varied between 1.5 and 1.9 (P = 0.02-0.05). ORS is an adverse event that is present with more than one vaccine and may be present with any influenza vaccines to a greater or lesser degree.
机译:我们评估了两种流感疫苗后的眼呼吸综合症(ORS)的发生情况:Fluviral(Shire Biologics)或Vaxigrip(Aventis Pasteur)。分别在5.3和4.6%的接受者中鉴定出ORS(P = 0.54)。使用这两种疫苗,上一年(2000年)患有ORS的个体的ORS风险要比没有这种病史的个体高得多。在多变量分析中,有ORS病史的患者ORS的优势比在9.4和9.6之间(P <0.001),而比较Fluviral®和Vaxigrip®的可能性在1.5和1.9之间(P = 0.02-0.05)。 )。 ORS是一种不良事件,它与一种以上的疫苗一起存在,并且可能与某种或多或少的流感疫苗一起出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号